Search

Author/Creator Fritsch, Holger

1. A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. (16th August 2013)

Authors:
Müller‐Tidow, Carsten; Bug, Gesine; Lübbert, Michael; Krämer, Alwin; Krauter, Jürgen; Valent, Peter; Nachbaur, David; Berdel, Wolfgang E.; Ottmann, Oliver G.; Fritsch, Holger; Munzert, Gerd; Garin‐Chesa, Pilar; Fleischer, Frank; Taube, Tillmann; Döhner, Hartmut
Journal:
British journal of haematology
Issue:
Volume 163:Number 2(2013:Oct.)
Page Start:
214
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). (February 2017)

Authors:
Awad, Mark M.; Chu, Quincy S-C; Gandhi, Leena; Stephenson, Joe J.; Govindan, Ramaswamy; Bradford, Daniel S.; Bonomi, Philip D.; Ellison, David M.; Eaton, Keith D.; Fritsch, Holger; Munzert, Gerd; Johnson, Bruce E.; Socinski, Mark A.
Journal:
Lung cancer
Issue:
Volume 104(2017)
Page Start:
126
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Issue 7 (11th December 2013)

Authors:
Stadler, Walter M.; Vaughn, David J.; Sonpavde, Guru; Vogelzang, Nicholas J.; Tagawa, Scott T.; Petrylak, Daniel P.; Rosen, Peter; Lin, Chia‐Chi; Mahoney, John; Modi, Sanjiv; Lee, Peter; Ernstoff, Marc S.; Su, Wu‐Chou; Spira, Alexander; Pilz, Korinna; Vinisko, Richard; Schloss, Charles; Fritsch, ...
Journal:
Cancer
Issue:
Volume 120:Issue 7(2014)
Page Start:
976
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Issue 7 (11th December 2013)

Authors:
Stadler, Walter M.; Vaughn, David J.; Sonpavde, Guru; Vogelzang, Nicholas J.; Tagawa, Scott T.; Petrylak, Daniel P.; Rosen, Peter; Lin, Chia‐Chi; Mahoney, John; Modi, Sanjiv; Lee, Peter; Ernstoff, Marc S.; Su, Wu‐Chou; Spira, Alexander; Pilz, Korinna; Vinisko, Richard; Schloss, Charles; Fritsch, ...
Journal:
Cancer
Issue:
Volume 120:Issue 7(2014)
Page Start:
976
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Issue 4 (April 2013)

Authors:
Vose, Julie M.; Friedberg, Jonathan W.; Waller, Edmund K.; Cheson, Bruce D.; Juvvigunta, Vasthala; Fritsch, Holger; Petit, Claude; Munzert, Gerd; Younes, Anas
Journal:
Leukemia & lymphoma
Issue:
Volume 54:Issue 4(2013:Apr.)
Page Start:
708
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗